Federal Register / Vol. 89, No. 42 / Friday, March 1, 2024 / Notices 15201 

38,585 banked vintage 2021–2023 

allowances will be held in facility or 

general accounts (84,378 current 

allowance holdings + 3,365 upcoming 

NUSA allocations¥49,158 reported 

2023 ozone season emissions = 38,585 

estimated remaining allowances). Based 

on these figures, EPA expects that 

allowance bank recalibration will take 

place for the 2024 control period and 

estimates that the amount of banked 

vintage 2021–2023 allowances that will 

be held in each facility or general 

account after recalibration will be the 

amount of such banked allowances held 

in the account immediately before 

recalibration multiplied by 12,605 and 

divided by 38,585 (or, equivalently, the 

amount of such banked allowances held 

in the account immediately before 

recalibration multiplied by 

approximately 33%). In the actual 

allowance bank recalibration process, 

instead of using the estimated figures 

described in this notice, EPA will use 

the most current information available 

as of the recalibration date. 

(Authority: 40 CFR 97.411(b), 97.511(b), 

97.611(b), 97.711(b), 97.811(b), and 

97.1012(a).) 

Rona Birnbaum, 

Director, Clean Air Markets Division, Office 

of Atmospheric Protection, Office of Air and 

Radiation. 

[FR Doc. 2024–04291 Filed 2–29–24; 8:45 am] 

BILLING CODE 6560–50–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Award of a Sole Source 

Cooperative Agreement To Fund 

Ministry of Health (MOH)—AIDS 

Control Program 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces the 

award of approximately $15,000,000, for 

Year 1 funding to MOH—AIDS Control 

Program. The award will support 

achievement of HIV epidemic control in 

Uganda by supporting the MOH to 

develop and disseminate key national 

policies and guidelines, increase 

technical capacity, ensure quality of 

health services, improve data quality 

and utilization, and provide leadership 

and direction to all partners engaged in 

the epidemic response. Funding 

amounts for years 2–5 will be set at 

continuation. 

DATES: The period for this award will be 

September 30, 2024, through September 

29, 2029. 

FOR FURTHER INFORMATION CONTACT: 

Kathy Grooms, Center for Global Health, 

Centers for Disease Control and 

Prevention, Embassy, Centers for 

Disease Control and Prevention 

Kampala, Uganda, Telephone: 

404.718.2578, Email: kwg1@cdc.gov. 

SUPPLEMENTARY INFORMATION: The sole 

source award(s) will strengthen 

technical and management capacity to 

review and develop key policies and 

guidelines and support the 

standardization and harmonization of 

the HIV/AIDS/TB response in Uganda. 

MOH—AIDS Control Program is in a 

unique position to conduct this work, as 

it has the authority, mandate, and 

ability to oversee, regulate, report on, 

and lead the overall health sector 

performance and activity 

implementation. No other entity can 

perform the duties of the MOH. The 

short-term success and long-term 

sustainability of HIV epidemic control, 

as well as general disease control and 

mitigation depend upon strong 

leadership and coordination from the 

MOH—AIDS Control Program. 

Summary of the Award 

Recipient: Ministry of Health 

(MOH)—AIDS Control Program. 

Purpose of the award: The purpose of 

this award is to support achievement of 

HIV epidemic control in Uganda by 

supporting the MOH to develop and 

disseminate key national policies and 

guidelines, increase technical capacity, 

ensure quality of health services, 

improve data quality and utilization, 

and provide leadership and direction to 

all partners engaged in the epidemic 

response. 

Amount of award: For MOH—AIDS 

Control Program, the approximate year 

1 funding amount will be $15,000,000 

in Federal Fiscal Year (FYY) 2024 

funds, subject to the availability of 

funds. Funding amounts for years 2–5 

will be set at continuation. 

Authority: This program is authorized 

under Public Law 108–25 (the United 

States Leadership Against HIV AIDS, 

Tuberculosis and Malaria Act of 2003) 

[22 U.S.C. 7601, et seq.] and Public Law 

110–293 (the Tom Lantos and Henry J. 

Hyde United States Global Leadership 

Against HIV/AIDS, Tuberculosis, and 

Malaria Reauthorization Act of 2008), 

and Public Law 113–56 (PEPFAR 

Stewardship and Oversight Act of 2013). 

Period of performance: The period for 

this award will be September 30, 2024, 

through September 29, 2029. 

Dated: February 26, 2024. 

Jamie Legier, 

Acting Director, Office of Grants Services, 

Centers for Disease Control and Prevention. 

[FR Doc. 2024–04404 Filed 2–29–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–10174 and CMS– 

R–64] 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 

(PRA), Federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, and to allow 

a second opportunity for public 

comment on the notice. Interested 

persons are invited to send comments 

regarding the burden estimate or any 

other aspect of this collection of 

information, including the necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions, the accuracy of 

the estimated burden, ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and the use 

of automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

DATES: Comments on the collection(s) of 

information must be received by the 

OMB desk officer by April 1, 2024. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 


ddrumheller on DSK120RN23PROD with NOTICES1
15202 Federal Register / Vol. 89, No. 42 / Friday, March 1, 2024 / Notices 

for Public Comments’’ or by using the 

search function. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, please access the CMS PRA 

website by copying and pasting the 

following web address into your web 

browser: https://www.cms.gov/ 

Regulations-and-Guidance/Legislation/ 

PaperworkReductionActof1995/PRAListing. 

FOR FURTHER INFORMATION CONTACT: 

William Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. The term ‘‘collection of 

information’’ is defined in 44 U.S.C. 

3502(3) and 5 CFR 1320.3(c) and 

includes agency requests or 

requirements that members of the public 

submit reports, keep records, or provide 

information to a third party. Section 

3506(c)(2)(A) of the PRA (44 U.S.C. 

3506(c)(2)(A)) requires Federal agencies 

to publish a 30-day notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension or 

reinstatement of an existing collection 

of information, before submitting the 

collection to OMB for approval. To 

comply with this requirement, CMS is 

publishing this notice that summarizes 

the following proposed collection(s) of 

information for public comment: 

1. Type of Information Collection 

Request: Revision with change of a 

currently approved collection; Title of 

Information Collection: Collection of 

Prescription Drug Data from MA–PD, 

PDP and Fallout Plans/Sponsors for 

Medicare Part D Payments; Use: The 

PDE data is used in the Payment 

Reconciliation System to perform the 

annual Part D payment reconciliation, 

any PDE data within the Coverage Gap 

Phase of the Part D benefit is used for 

invoicing in the CGDP, and the data are 

part of the report provided to the 

Secretary of the Treasury for Section 

9008. 

Sections 11001 through 11004 of the 

Inflation Reduction Act of 2022 

establish a Medicare Drug Negotiation 

Program for high-expenditure drugs. 

Section 11102 of the Inflation Reduction 

Act of 2022 establishes a Part D inflation 

rebate by manufacturers of certain single 

source drugs and biologicals with prices 

increasing at a rate faster than the rate 

of inflation. CMS will use data reported 

under sections 1860D–15(c)(1)(C) and 

(d)(2), in part, to rank drugs by total 

expenditures under Part D in order to 

select drugs for negotiation and to 

identify units to calculate inflation 

rebates. 

The information users will be 

pharmacy benefit managers (PBMs), 

third party administrators and 

pharmacies, and the PDPs, MA–PDs, 

Fallbacks, and other plans that offer 

coverage of outpatient prescription 

drugs under the Medicare Part D benefit 

to Medicare beneficiaries. The 

statutorily required data is used 

primarily for payment and is used for 

claim validation as well as for other 

legislated functions such as quality 

monitoring, program integrity and 

oversight. In addition, the PDE data are 

used to support operations and program 

development. Form Number: CMS– 

10174 (OMB control number: 0938– 

0982); Frequency: Monthly; Affected 

Public: Private sector and Federal 

Government; Number of Respondents: 

856; Total Annual Responses: 

1,499,064,780; Total Annual Hours: 

62,918. (For policy questions regarding 

this collection contact Shelly Winston at 

410–786–3694.) 

2. Type of Information Collection 

Request: Reinstatement without change 

of a previously approved collection; 

Title of Information Collection: Indirect 

Medical Education and Direct Graduate 

Medical Education; Use: Section 

1886(d)(5)(B) of the Social Security Act 

requires additional payments to be 

made under the Medicare Prospective 

Payment System (PPS) for the indirect 

medical educational costs a hospital 

incurs in connection with interns and 

residents (IRs) in approved teaching 

programs. In addition, title 42, part 413, 

sections 75 through 83 implement 

section 1886(d) of the Act by 

establishing the methodology for 

Medicare payment for the costs of direct 

graduate medical educational activities. 

The information collected on IRs is 

used by Part- A Medicare 

Administrative Contractors (MAC) to 

verify the number of IRs FTE used in the 

calculation of Medicare payments for 

IME and GME. The IR data submitted by 

the hospitals to the MACs is uploaded 

into CMS’ Intern and Resident 

Information System (IRIS) database to 

identify duplicate FTEs reported for any 

IR. 

The MACs use the information 

collected on IRs to ensure that all 

program payments for IME and GME are 

accurate and are in accordance with 

Medicare regulations. The IR data 

submitted by the hospitals to the MACs 

are used to audit the Medicare cost 

reports filed by the hospitals. Form 

Number: CMS–R–64 (OMB control 

number: 0938–0456); Frequency: 

Monthly; Affected Public: Private sector 

and Federal Government; Number of 

Respondents: 1,245; Total Annual 

Responses: 1,245; Total Annual Hours: 

2,490. (For policy questions regarding 

this collection contact Owen Osaghae at 

410–786–7550.) 

William N. Parham, III, 

Director, Division of Information Collections 

and Regulatory Impacts, Office of Strategic 

Operations and Regulatory Affairs. 

[FR Doc. 2024–04341 Filed 2–29–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2004–N–0451] 

Food and Drug Administration 

Modernization Act of 1997: 

Modifications to the List of Recognized 

Standards, Recognition List Number: 

061 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing a publication containing 

modifications the Agency is making to 

the list of standards FDA recognizes for 

use in premarket reviews (FDA 

Recognized Consensus Standards). This 

publication, entitled ‘‘Modifications to 

the List of Recognized Standards, 

Recognition List Number: 061’’ 

(Recognition List Number: 061), will 

assist manufacturers who elect to 

declare conformity with consensus 

standards to meet certain requirements 

for medical devices. 

DATES: Submit either electronic or 

written comments on the notice at any 

time. These modifications to the list of 

recognized standards are applicable 

March 1, 2024. 

ADDRESSES: You may submit comments 

on the current list of FDA Recognized 

Consensus Standards at any time as 

follows: 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 


ddrumheller on DSK120RN23PROD with NOTICES1